Phase Ib multiple ascending dose trial of DB 959 in volunteers

Trial Profile

Phase Ib multiple ascending dose trial of DB 959 in volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jun 2012

At a glance

  • Drugs T3D 959 (Primary)
  • Indications Dyslipidaemias; Type 2 diabetes mellitus
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 12 Jun 2012 Results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
    • 08 Nov 2011 Status changed from recruiting to completed.
    • 01 Nov 2011 Positive results from this trial presented in a DARA Biosciences media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top